<div id="hybrid-search-3" class="widget search widget-search"><div class="widget-inside"><form method="get" class="search-form" id="search-form" action="https://rare-diseases.ca/"><div><input class="search-text" type="text" name="s" id="search-text" value="" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" /><input class="search-submit button" name="submit" type="submit" id="search-submit" value="Search" /></div></form><!-- .search-form --></div></div>
Rare Diseases
<div id="hybrid-nav-menu-3" class="widget nav-menu widget-nav-menu"><div class="widget-inside">
</div></div>
<div class="breadcrumb breadcrumbs"><div class="breadcrumb-trail"> » <a href="https://rare-diseases.ca" title="" rel="home" class="trail-begin">Home</a> <span class="sep">»</span> <a href="https://rare-diseases.ca/2012/" title="2012">2012</a> <span class="sep">»</span> March </div></div>

March 2012

You are browsing the archive for March 2012.

<img width="125" height="100" src="https://rare-diseases.ca/files/2012/08/imagesCA8S1GAU-125x100.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" />

Orphan drug policies make drug research for rare diseases viable in the U.S. but not in Canada

Business in Vancouver, March 20, 2012
From a sheer market perspective, Allon Therapeutics’ decision to focus on a rare a neurological disorder called progressive supranuclear palsy (PSP) doesn’t add up. After all, only 20,000 North Americans have the disease, compared with 4.4 million Alzheimer’s victims….